Introduction/Background Radical vaginal trachelectomy is an oncological safe treatment option for patients with early stage cervical cancer wishing to preserve fertility. However, the procedure remains controverse due to the radicality and obstetric and perioperative complications.

We performed a retrospective monocentric study of 107 RVT cases and analysed the follow up results in terms of oncologic outcome, pregnancy and delivery rate, persistence or recurrence of HPV, recurrence of cytological abnormalities and long term morbidities.

Methodology 107 patients who underwent radical vaginal trachelectomy at University Hospital Jena between 1998 and 2020 were included. Inclusion criteria: patients aged 21 to 41 years, cervical cancer stage Ia1 to Ib2, any tumor size, regardless of neoadjuvant chemotherapy, regardless of histotype. Exclusion criteria: patients who underwent hysterectomy in the first 6 months after trachelectomy, patients with no follow up or follow up shorter than 6 months

Results Out of 107 patients, 77 (71%) attended the follow up appointments. There were three cases of recurrent disease making 2.8% from total resp. 3.8% from the follow up cases. One case of recurrent disease was large cell carcinoma, one was adenocarcinoma and one had LVSI. The HPV test showed persistent or reinfection in 10 cases (12%). HPV Infection did not correlate with premalignant lesions or recurrent cases. The postoperative complications were cervical stenosis (6.4%) and lymphedema (7.7%). Fourteen patients got pregnant (14/77, 18%). The delivery rate was 64% (9/14), five deliveries were after 36 pregnancy weeks, and four deliveries were premature.

Conclusion RVT is an oncological safe procedure with acceptable postoperative morbidity and obstetric outcome. HPV reinfection rate is quite high and might raise the question of vaccination after trachelectomy.

Disclosures No conflict of interest for main author and co-authors.